Endoscopic severity and C-reactive protein predict initial and 12-month outcomes of second-line medical therapy in acute severe ulcerative colitis: the RESCUE-ASC study

Objective Medical rescue therapy (MRT) is effective in intravenous corticosteroid refractory acute severe ulcerative colitis (ASUC). Our aim was to identify predictors of response to MRT and avoid colectomy in the index admission or within 12 months. Methods Two cohorts were studied retrospectively. Analysis of 49 adults receiving MRT between 2015 and 2019 at two tertiary Australian hospitals was first performed. Clinical, endoscopic and laboratory data were collected. Response was defined as avoiding colectomy during the same admission. Univariable and multivariable logistic regression were employed to identify predictors of response. The predictors were validated in 88 patients receiving MRT between 2020 and 2023. Results In the development cohort, 40/49 (81.6%) patients responded to MRT. On multivariable analysis, Ulcerative Colitis Endoscopic Index of Severity (UCEIS) score at admission (Coef −0.105 (−0.19 to –0.007), p=0.03) and C-reactive protein (CRP) on day 3 of post commencement of MRT (CRP-R+3) (Coef −0.004 (−0.0008 to −0.0004), p=0.03) identified response to MRT. All patients (n=17) with a UCEIS score <6 (UCEIS <6) and 100% (n=28) patients with a CRP-R+3 <22 mg/L responded to MRT. In the validation cohort, 82/88 (93.1%) patients responded to MRT; 90.5% (19/21) with UCEIS <6 and 100% (70/70) patients with CRP-R+3 <22 mg/L responded to MRT. At 12 months after hospitalisation for ASUC, in the development cohort, 16/17 (94%) patients with a UCEIS <6 and 23/28 (82.1%) patients with CRP-R+3 <22 mg/L avoided colectomy. In the validation cohort, 18/21 (85.7%) with UCEIS <6 and 64/70 (91.4%) patients with CRP-R +3 <22 mg/L avoided colectomy at 12 months. Conclusions UCEIS <6 and CRP-R+3 <22mg/L identify responders to MRT, and colectomy is extremely unlikely either on the index admission or within 12 months.

Authors

Institutions

Publication Details

Journal
Frontline Gastroenterology
Published
2025-10-02
DOI
https://doi.org/10.1136/flgastro-2025-103253
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Endoscopic severity and C-reactive protein predict initial and 12-month outcomes of second-line medical therapy in acute severe ulcerative colitis: the RESCUE-ASC study

Maneesha Bhullar, Laura Willmann, Jack Satsangi, Pradeep Kakkadasam Ramaswamy et al.
Frontline Gastroenterology
Inflammatory Bowel Disease
article

Endoscopic severity and C-reactive protein predict initial and 12-month outcomes of second-line medical therapy in acute severe ulcerative colitis: the RESCUE-ASC study

Maneesha Bhullar, Laura Willmann, Jack Satsangi, Pradeep Kakkadasam Ramaswamy, Deloshaan Subhaharan, Asif Shahzad, Alexander Dorrington, Desmond Patrick, Thomas Chapman, Naveed Ishaq, Waled Mohsen, Lauren S. White, John Edwards, Dheeraj Shukla
article en

Abstract

Objective Medical rescue therapy (MRT) is effective in intravenous corticosteroid refractory acute severe ulcerative colitis (ASUC). Our aim was to identify predictors of response to MRT and avoid colectomy in the index admission or within 12 months. Methods Two cohorts were studied retrospectively. Analysis of 49 adults receiving MRT between 2015 and 2019 at two tertiary Australian hospitals was first performed. Clinical, endoscopic and laboratory data were collected. Response was defined as avoiding colectomy during the same admission. Univariable and multivariable logistic regression were employed to identify predictors of response. The predictors were validated in 88 patients receiving MRT between 2020 and 2023. Results In the development cohort, 40/49 (81.6%) patients responded to MRT. On multivariable analysis, Ulcerative Colitis Endoscopic Index of Severity (UCEIS) score at admission (Coef −0.105 (−0.19 to –0.007), p=0.03) and C-reactive protein (CRP) on day 3 of post commencement of MRT (CRP-R+3) (Coef −0.004 (−0.0008 to −0.0004), p=0.03) identified response to MRT. All patients (n=17) with a UCEIS score <6 (UCEIS <6) and 100% (n=28) patients with a CRP-R+3 <22 mg/L responded to MRT. In the validation cohort, 82/88 (93.1%) patients responded to MRT; 90.5% (19/21) with UCEIS <6 and 100% (70/70) patients with CRP-R+3 <22 mg/L responded to MRT. At 12 months after hospitalisation for ASUC, in the development cohort, 16/17 (94%) patients with a UCEIS <6 and 23/28 (82.1%) patients with CRP-R+3 <22 mg/L avoided colectomy. In the validation cohort, 18/21 (85.7%) with UCEIS <6 and 64/70 (91.4%) patients with CRP-R +3 <22 mg/L avoided colectomy at 12 months. Conclusions UCEIS <6 and CRP-R+3 <22mg/L identify responders to MRT, and colectomy is extremely unlikely either on the index admission or within 12 months.

Frontline Gastroenterology
Gold Coast Hospital (AU), Logan Hospital (AU), University of Oxford (GB), Sunshine Coast University Hospital (AU), Oxford BioMedica (United Kingdom) (GB), University Hospitals Sussex NHS Foundation Trust (GB)
Openalex Percentile: Top 71%
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.